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Purpose
Abacavir use has been associated with an increased risk
of ischemic cardiovascular events in several cohort stu-
dies, but the pathogenic mechanisms are still unknown.
Recently Martinez et al. observed no differences in mar-
kers of inflammation, endothelial dysfunction, insulin
resistance or hypercoagulability in HIV infected persons
t r e a t e dw i t he i t h e ra b a c a v i ro rt e n o f o v i r .W h i l es e v e r a l
studies have shown endothelial dysfunction in HIV-
infected patients, only a few data are available on the
involvement of platelets. Aim of our study was to evalu-
ate markers of platelet activation and endothelial dys-
function in HIV infection comparing patients treated
with abacavir or tenofovir.
Methods
In a retrospective, case-control study, the time course of
some endothelial (MCP-1, sVCAM-1) and platelet acti-
vation markers (sPLA2, sGPV,s P - s e l )w a se x a m i n e di n
62 HIV-infected patients, before starting HAART and
after 6-12 months of therapy with either Abacavir
(n=31) or Tenofovir (n=31). Data were compared with
those from 20 untreated HIV-infected patients at diag-
nosis and after 6 months and 10 healthy matched
controls.
Results
Soluble P-selectin (sP-sel), sPLA2, soluble vascular cell
adhesion molecule-1 (sVCAM-1) and monocyte che-
moattractant protein-1 (MCP-1) were significantly
higher in HIV-infected patients than in healthy controls.
During 6-12 months of follow-up, we found no
significant differences between abacavir and tenofovir-
treatment for endothelial markers, while sPLA2 (2113.6
±39.5 vs 2742.5±29.7pg/ml, p<0.05) and sPsel (524±53.2
vs 713.47±20.3ng/ml, p<0.05) increased significantly in
the abacavir group as compared with the tenofovir-trea-
ted group. sGPV, the platelet glycoprotein V major frag-
ment released upon thrombin cleavage, was increased
after 6-12 months as compared to baseline in both treat-
ment groups (Abacavir: 89.7±13.7 vs 118.64±15.3 ng/ml
Tenofovir: 133.5±10.7 vs 157.36±11.2, p<0.05). In naïve
patients, not treated with HAART, significantly
increased plasma markers of endothelial dysfunction
sPsel and sPLA2 were confirmed at diagnosis, as com-
pared with healthy controls, with no changes upon fol-
low-up.
Conclusions
Our results confirm that chronic HIV infection induces
endothelial dysfunction but indicate that a short-term
treatment with abacavir enhances also some parameters
of platelet activation, suggesting a role of platelets too in
the increased incidence of ischemic cardiovascular
events in HIV-infected patients treated with abacavir.
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